Dobutamine Hydrochloride — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	IV	2-20 mcg/kg/min	Continuous rate infusion (CRI)	Duration: As needed; titrate to effect Notes: Start at low end and titrate to achieve desired cardiac output and blood pressure. Monitor ECG and blood pressure.
Cat	IV	2-10 mcg/kg/min	Continuous rate infusion (CRI)	Duration: As needed; titrate to effect Notes: Cats may be more sensitive; use lower doses and monitor closely.
Horse	IV	2-10 mcg/kg/min	Continuous rate infusion (CRI)	Duration: As needed; titrate to effect Notes: Monitor for arrhythmias and blood pressure.
Cattle	IV	2-10 mcg/kg/min	Continuous rate infusion (CRI)	Duration: As needed; titrate to effect Notes: Use with caution in cattle; monitor cardiovascular status.
Small Ruminants	IV	2-10 mcg/kg/min	Continuous rate infusion (CRI)	Duration: As needed; titrate to effect Notes: Limited data; use cautiously.
Rabbit	IV	2-10 mcg/kg/min	Continuous rate infusion (CRI)	Duration: As needed; titrate to effect Notes: Limited data; use cautiously.

Clinical Indications & Species Uses

General Indications

Acute heart failure
Cardiogenic shock
Hypotension during anesthesia or critical care

Dog (Canine)

Acute heart failure
Cardiogenic shock
Anesthetic-induced hypotension
Support during cardiac surgery

Cat (Feline)

Acute heart failure
Cardiogenic shock
Anesthetic-induced hypotension

Horse (Equine)

Acute heart failure
Cardiogenic shock
Hypotension during anesthesia

Cattle (Bovine)

Acute heart failure
Cardiogenic shock
Hypotension during anesthesia

Small Ruminants (Sheep / Goat)

Acute heart failure
Cardiogenic shock
Hypotension during anesthesia

Rabbit & Small Mammals

Acute heart failure
Cardiogenic shock
Hypotension during anesthesia

Pharmacology & Mechanism of Action

Drug Class: Sympathomimetic Agent | Pharmacological Group: Catecholamine; Inotropic Agent

Mechanism of Action: Dobutamine is a synthetic catecholamine that primarily stimulates beta-1 adrenergic receptors in the heart, producing positive inotropic effects with minimal chronotropic and arrhythmogenic effects at therapeutic doses. It also has mild beta-2 and alpha-1 adrenergic activity. The net effect is increased myocardial contractility and stroke volume, leading to increased cardiac output. It does not significantly increase myocardial oxygen demand compared to other inotropes, and its chronotropic effect is less pronounced than that of dopamine or isoproterenol.

Pharmacodynamics: Dobutamine increases cardiac contractility and cardiac output by enhancing myocardial calcium influx. It also causes mild peripheral vasodilation due to beta-2 agonism, which can reduce afterload. At higher doses, alpha-1 mediated vasoconstriction may occur, but the overall effect is usually a slight decrease in systemic vascular resistance. It has minimal effect on renal and mesenteric blood flow compared to dopamine. Dobutamine is used to treat acute heart failure and cardiogenic shock, improving tissue perfusion and oxygen delivery.

⚡ Pharmacokinetics Summary

Absorption: Dobutamine is not effective orally; it is administered intravenously. Onset of action is within 1-2 minutes after IV administration.

Distribution: Dobutamine is widely distributed in the body. It crosses the placenta but has low penetration into the CNS. Volume of distribution is approximately 0.2 L/kg in humans; similar in animals.

Metabolism: Dobutamine is rapidly metabolized in the liver and plasma by catechol-O-methyltransferase (COMT) to inactive metabolites. It is also conjugated with glucuronide.

Excretion: Metabolites are excreted primarily in the urine, with a small amount in feces. The elimination half-life is short, approximately 2 minutes in dogs and cats.

Half-Life: Dogs: ~2 minutes; Cats: ~2 minutes; Horses: ~2-3 minutes; Cattle: ~2 minutes

Bioavailability: Not applicable (IV only)

Protein Binding: Low protein binding (approximately 20-30%)

Available Formulations & Strengths

Injectable Solution 12.5 mg/mL (250 mg/20 mL) (IV)

Concentrate for IV infusion 250 mg/20 mL (12.5 mg/mL) (IV)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to dobutamine or sulfites (some formulations contain sulfites)
Idiopathic hypertrophic subaortic stenosis (IHSS)
Severe aortic stenosis
Hypovolemia (should be corrected before administration)
Concurrent use with MAO inhibitors (risk of hypertensive crisis)

Warnings & Clinical Precautions:

Use with extreme caution in patients with arrhythmias, especially ventricular arrhythmias.
May increase heart rate and cause tachyarrhythmias; monitor ECG continuously.
Correct hypovolemia before administration to avoid worsening hypotension.
Use with caution in patients with myocardial ischemia or recent myocardial infarction.
In cats, may cause more pronounced tachycardia and arrhythmias; use lower doses.
Extravasation can cause tissue necrosis; administer via central line if possible.
Monitor blood pressure, heart rate, ECG, and urine output during infusion.
Taper infusion gradually to avoid rebound hypotension.

Adverse Effects & Reactions

Common:

Tachycardia
Ventricular arrhythmias
Hypotension (at high doses)
Hypertension (at high doses)
Injection site reactions

Serious / Severe:

Ventricular fibrillation
Myocardial ischemia
Cardiac arrest
Tissue necrosis (extravasation)

Rare:

Hypersensitivity reactions
Thrombocytopenia
Eosinophilia

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Beta-blockers (e.g., propranolol)	May antagonize the inotropic effects of dobutamine.	Moderate
MAO inhibitors (e.g., selegiline)	May potentiate the pressor effects, leading to hypertensive crisis.	High
Inhalational anesthetics (e.g., halothane)	May increase the risk of arrhythmias.	Moderate
Vasodilators (e.g., nitroprusside)	Additive hypotensive effects.	Moderate
Diuretics (e.g., furosemide)	May exacerbate hypokalemia, increasing risk of arrhythmias.	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Severe tachycardia
Arrhythmias (ventricular tachycardia, fibrillation)
Hypertension or hypotension
Tremors
Seizures
Cardiac arrest

Emergency Treatment Protocol: Discontinue infusion immediately. Provide supportive care: maintain airway, monitor ECG, treat arrhythmias with appropriate antiarrhythmics (e.g., lidocaine for ventricular arrhythmias). Administer fluids if hypotensive, but avoid fluid overload. In severe cases, use beta-blockers (e.g., esmolol) to counteract excessive beta-1 stimulation. Treat seizures with diazepam if necessary.

Food Animal Withdrawal Times

Not approved for food animals; withdrawal times not established. Use in food animals is off-label and requires veterinary oversight; consult regulatory guidelines.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F); protect from light.

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Do not freeze. Diluted solutions should be used within 24 hours if stored at room temperature, or 48 hours if refrigerated. Discard any unused portion.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use.

Extra-Label (Off-Label) Use: In the US, dobutamine is not FDA-approved for veterinary use; use in animals is extra-label. Must follow AMDUCA regulations: require valid VCPR, and withdrawal times must be extended if used in food animals.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Dobutamine is a potent inotrope used in emergency and critical care settings for acute heart failure and cardiogenic shock. It is administered as a continuous IV infusion with careful titration based on patient response. Continuous monitoring of heart rate, blood pressure, ECG, and central venous pressure is essential. In veterinary medicine, it is commonly used in dogs and cats, but less frequently in large animals due to cost and availability. Extravasation must be avoided; if it occurs, infiltrate with phentolamine. Dobutamine should be used as part of a comprehensive treatment plan including fluid therapy, oxygen supplementation, and treatment of underlying causes. It is not a substitute for definitive therapy. Due to its short half-life, effects cease rapidly after discontinuation. Use with caution in patients with pre-existing arrhythmias or electrolyte imbalances.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)